Erin L. Polek Sells 1478 Shares of QUALCOMM, Inc. (NASDAQ:QCOM) Stock

QUALCOMM, Inc. (NASDAQ:QCOM) SVP Erin L. Polek sold 1,478 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares …

QUALCOMM logoQUALCOMM, Inc. (NASDAQ:QCOM) SVP Erin L. Polek sold 1,478 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $70.36, for a total transaction of $103,992.08. Following the transaction, the senior vice president now owns 1,386 shares in the company, valued at $97,518.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

QUALCOMM stock traded up $0.38 on Wednesday, hitting $74.35. 5,059,817 shares of the stock traded hands, compared to its average volume of 16,320,214. The business’s fifty day simple moving average is $73.68 and its 200 day simple moving average is $68.65. The company has a current ratio of 1.77, a quick ratio of 1.61 and a debt-to-equity ratio of 2.46. The firm has a market cap of $89.38 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.03 and a beta of 1.62. QUALCOMM, Inc. has a 1 year low of $49.10 and a 1 year high of $90.34.

QUALCOMM (NASDAQ:QCOM) last released its quarterly earnings data on Wednesday, July 31st. The wireless technology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The company had revenue of $4.89 billion during the quarter, compared to the consensus estimate of $5.12 billion. QUALCOMM had a return on equity of 112.21% and a net margin of 13.41%. QUALCOMM’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same period last year, the company earned $1.01 EPS. As a group, analysts predict that QUALCOMM, Inc. will post 2.84 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 26th. Investors of record on Thursday, September 12th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Wednesday, September 11th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 3.34%. QUALCOMM’s dividend payout ratio (DPR) is presently 77.74%.

Several large investors have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd grew its stake in shares of QUALCOMM by 4.8% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 1,992,405 shares of the wireless technology company’s stock valued at $151,562,000 after acquiring an additional 91,605 shares during the period. EP Wealth Advisors LLC lifted its holdings in QUALCOMM by 41.4% in the 2nd quarter. EP Wealth Advisors LLC now owns 12,900 shares of the wireless technology company’s stock worth $981,000 after purchasing an additional 3,777 shares in the last quarter. Boston Partners purchased a new position in QUALCOMM in the 2nd quarter worth approximately $6,527,000. Treasurer of the State of North Carolina lifted its holdings in QUALCOMM by 2.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 794,427 shares of the wireless technology company’s stock worth $60,432,000 after purchasing an additional 18,190 shares in the last quarter. Finally, RFG Advisory LLC lifted its holdings in QUALCOMM by 7.7% in the 2nd quarter. RFG Advisory LLC now owns 19,276 shares of the wireless technology company’s stock worth $1,460,000 after purchasing an additional 1,382 shares in the last quarter. Institutional investors own 79.55% of the company’s stock.

A number of research analysts have commented on the stock. Mizuho set a $68.00 price target on shares of QUALCOMM and gave the company a “hold” rating in a research report on Monday. Raymond James upgraded shares of QUALCOMM from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $85.00 to $115.00 in a report on Thursday, May 2nd. Zacks Investment Research upgraded shares of QUALCOMM from a “sell” rating to a “hold” rating in a report on Monday, May 6th. Morgan Stanley set a $89.00 target price on shares of QUALCOMM and gave the stock a “buy” rating in a report on Wednesday, August 21st. Finally, Rosenblatt Securities restated a “buy” rating and issued a $84.00 target price on shares of QUALCOMM in a report on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $79.69.

QUALCOMM Company Profile

QUALCOMM Incorporated designs, develops, manufactures, and markets digital communication products worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access, and other technologies for use in wireless voice and data communications, networking, application processing, multimedia, and global positioning system products.

See Also: What is a short straddle?

Insider Buying and Selling by Quarter for QUALCOMM (NASDAQ:QCOM)

Receive News & Ratings for QUALCOMM Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QUALCOMM and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Appleton Partners Inc. MA Cuts Stock Position in NVIDIA Co. (NASDAQ:NVDA)

Appleton Partners Inc. MA trimmed its stake in NVIDIA Co. (NASDAQ:NVDA) by 12.5% in the second quarter, according to the company in its most …

NVIDIA logoAppleton Partners Inc. MA trimmed its stake in NVIDIA Co. (NASDAQ:NVDA) by 12.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,965 shares of the computer hardware maker’s stock after selling 281 shares during the quarter. Appleton Partners Inc. MA’s holdings in NVIDIA were worth $323,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bay Harbor Wealth Management LLC lifted its stake in shares of NVIDIA by 41.4% in the first quarter. Bay Harbor Wealth Management LLC now owns 205 shares of the computer hardware maker’s stock worth $37,000 after acquiring an additional 60 shares in the last quarter. LS Investment Advisors LLC raised its stake in NVIDIA by 0.5% during the first quarter. LS Investment Advisors LLC now owns 11,952 shares of the computer hardware maker’s stock valued at $2,146,000 after buying an additional 62 shares in the last quarter. McIlrath & Eck LLC raised its stake in NVIDIA by 14.5% during the first quarter. McIlrath & Eck LLC now owns 496 shares of the computer hardware maker’s stock valued at $89,000 after buying an additional 63 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in NVIDIA by 19.8% during the first quarter. Tradewinds Capital Management LLC now owns 393 shares of the computer hardware maker’s stock valued at $71,000 after buying an additional 65 shares in the last quarter. Finally, Sky Investment Group LLC raised its stake in NVIDIA by 0.9% during the first quarter. Sky Investment Group LLC now owns 7,160 shares of the computer hardware maker’s stock valued at $1,286,000 after buying an additional 67 shares in the last quarter. 66.93% of the stock is owned by institutional investors.

In other news, CFO Colette Kress sold 2,236 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $164.01, for a total value of $366,726.36. Following the transaction, the chief financial officer now owns 239,710 shares in the company, valued at approximately $39,314,837.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Persis Drell sold 2,500 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $166.80, for a total transaction of $417,000.00. Following the completion of the transaction, the director now owns 20,684 shares in the company, valued at approximately $3,450,091.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 127,236 shares of company stock worth $19,060,326. Insiders own 4.64% of the company’s stock.

NVDA stock traded down $0.58 during midday trading on Wednesday, reaching $161.22. The company had a trading volume of 6,279,187 shares, compared to its average volume of 13,037,354. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.65 and a quick ratio of 7.74. NVIDIA Co. has a 1 year low of $124.46 and a 1 year high of $292.76. The company has a market capitalization of $98.93 billion, a P/E ratio of 26.56, a P/E/G ratio of 4.16 and a beta of 2.07. The firm has a 50-day moving average price of $164.42 and a 200-day moving average price of $164.21.

NVIDIA (NASDAQ:NVDA) last announced its quarterly earnings data on Thursday, August 15th. The computer hardware maker reported $1.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.37. The company had revenue of $2.58 billion for the quarter, compared to the consensus estimate of $2.55 billion. NVIDIA had a net margin of 26.93% and a return on equity of 24.40%. NVIDIA’s revenue for the quarter was down 17.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.94 EPS. On average, equities analysts predict that NVIDIA Co. will post 4.08 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, August 29th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Wednesday, August 28th. NVIDIA’s payout ratio is presently 10.54%.

A number of brokerages have recently weighed in on NVDA. Mizuho reiterated a “buy” rating and set a $185.00 price target (down from $192.00) on shares of NVIDIA in a research report on Friday, August 16th. Oppenheimer set a $190.00 price objective on NVIDIA and gave the stock a “buy” rating in a report on Friday, August 16th. Sanford C. Bernstein set a $150.00 price target on NVIDIA and gave the company a “hold” rating in a research note on Wednesday, June 26th. BidaskClub raised NVIDIA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, Bank of America restated a “buy” rating on shares of NVIDIA in a report on Tuesday, August 20th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and twenty-eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $190.40.

About NVIDIA

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the Graphics Processing Unit (GPU) and Tegra Processor segments. The GPU segment comprises of product brands which aims specialized markets including GeForce for gamers; Quadro for designers; Tesla and DGX for AI data scientists and big data researchers; and GRID for cloud-based visual computing users.

Featured Story: How analysts view the yield curve

Institutional Ownership by Quarter for NVIDIA (NASDAQ:NVDA)

Receive News & Ratings for NVIDIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NVIDIA and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

KBC Group NV Reduces Position in NVIDIA Co. (NASDAQ:NVDA)

KBC Group NV trimmed its stake in NVIDIA Co. (NASDAQ:NVDA) by 0.0% during the second quarter, HoldingsChannel reports. The institutional …

NVIDIA logoKBC Group NV trimmed its stake in NVIDIA Co. (NASDAQ:NVDA) by 0.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 334,806 shares of the computer hardware maker’s stock after selling 162 shares during the period. KBC Group NV’s holdings in NVIDIA were worth $54,985,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of NVDA. Thor Advisors LLC purchased a new position in shares of NVIDIA in the 1st quarter valued at $29,000. Harvest Group Wealth Management LLC acquired a new stake in NVIDIA during the 1st quarter worth $30,000. Field & Main Bank acquired a new stake in NVIDIA during the 2nd quarter worth $33,000. Sound Income Strategies LLC boosted its stake in NVIDIA by 96.2% during the 2nd quarter. Sound Income Strategies LLC now owns 204 shares of the computer hardware maker’s stock worth $34,000 after purchasing an additional 100 shares during the period. Finally, Semmax Financial Advisors Inc. boosted its stake in NVIDIA by 935.0% during the 1st quarter. Semmax Financial Advisors Inc. now owns 207 shares of the computer hardware maker’s stock worth $37,000 after purchasing an additional 187 shares during the period. 66.93% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:NVDA opened at $161.80 on Wednesday. The company has a current ratio of 8.65, a quick ratio of 7.74 and a debt-to-equity ratio of 0.24. The firm has a 50-day moving average price of $164.31 and a two-hundred day moving average price of $164.14. NVIDIA Co. has a twelve month low of $124.46 and a twelve month high of $292.76. The company has a market capitalization of $98.93 billion, a P/E ratio of 26.66, a price-to-earnings-growth ratio of 4.16 and a beta of 2.07.

NVIDIA (NASDAQ:NVDA) last posted its earnings results on Thursday, August 15th. The computer hardware maker reported $1.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.37. NVIDIA had a net margin of 26.93% and a return on equity of 24.40%. The firm had revenue of $2.58 billion during the quarter, compared to the consensus estimate of $2.55 billion. During the same period last year, the firm posted $1.94 EPS. The firm’s revenue for the quarter was down 17.4% on a year-over-year basis. On average, equities research analysts predict that NVIDIA Co. will post 4.08 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 29th will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, August 28th. This represents a $0.64 annualized dividend and a yield of 0.40%. NVIDIA’s dividend payout ratio (DPR) is currently 10.54%.

In other NVIDIA news, Director Dawn E. Hudson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $171.73, for a total transaction of $858,650.00. Following the completion of the transaction, the director now directly owns 36,037 shares in the company, valued at approximately $6,188,634.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Colette Kress sold 2,236 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $164.01, for a total transaction of $366,726.36. Following the transaction, the chief financial officer now owns 239,710 shares of the company’s stock, valued at $39,314,837.10. The disclosure for this sale can be found here. Insiders have sold a total of 112,236 shares of company stock valued at $16,570,776 over the last 90 days. 4.64% of the stock is currently owned by insiders.

A number of analysts recently weighed in on the stock. Craig Hallum reiterated a “hold” rating and set a $170.00 price target (up previously from $165.00) on shares of NVIDIA in a research note on Friday, August 16th. Benchmark restated a “buy” rating and issued a $210.00 target price on shares of NVIDIA in a research note on Wednesday, August 21st. BidaskClub upgraded shares of NVIDIA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Summit Redstone cut shares of NVIDIA to a “hold” rating in a research note on Friday, May 17th. Finally, UBS Group reduced their target price on shares of NVIDIA from $210.00 to $195.00 and set a “buy” rating for the company in a research note on Friday, May 17th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and twenty-eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $190.40.

About NVIDIA

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the Graphics Processing Unit (GPU) and Tegra Processor segments. The GPU segment comprises of product brands which aims specialized markets including GeForce for gamers; Quadro for designers; Tesla and DGX for AI data scientists and big data researchers; and GRID for cloud-based visual computing users.

Recommended Story: G-20

Want to see what other hedge funds are holding NVDA?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Co. (NASDAQ:NVDA).

Institutional Ownership by Quarter for NVIDIA (NASDAQ:NVDA)

Receive News & Ratings for NVIDIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NVIDIA and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Corient Capital Partners LLC Buys 329 Shares of Broadcom Inc (NASDAQ:AVGO)

Corient Capital Partners LLC raised its stake in Broadcom Inc (NASDAQ:AVGO) by 3.9% during the second quarter, HoldingsChannel reports.

Broadcom logoCorient Capital Partners LLC raised its stake in Broadcom Inc (NASDAQ:AVGO) by 3.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 8,857 shares of the semiconductor manufacturer’s stock after acquiring an additional 329 shares during the period. Corient Capital Partners LLC’s holdings in Broadcom were worth $2,550,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in shares of Broadcom by 6.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,644,308 shares of the semiconductor manufacturer’s stock valued at $418,142,000 after purchasing an additional 96,233 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Broadcom by 1.4% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 67,858 shares of the semiconductor manufacturer’s stock valued at $20,406,000 after purchasing an additional 921 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of Broadcom by 22.0% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 126,218 shares of the semiconductor manufacturer’s stock valued at $37,955,000 after purchasing an additional 22,789 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in Broadcom by 75.6% during the 1st quarter. Quadrant Capital Group LLC now owns 2,515 shares of the semiconductor manufacturer’s stock valued at $736,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Whittier Trust Co. increased its holdings in Broadcom by 18.8% during the 1st quarter. Whittier Trust Co. now owns 30,880 shares of the semiconductor manufacturer’s stock valued at $9,285,000 after acquiring an additional 4,889 shares in the last quarter. Hedge funds and other institutional investors own 83.13% of the company’s stock.

In other news, insider Hock E. Tan sold 20,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $292.16, for a total transaction of $5,843,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Bryan Ingram sold 13,466 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $278.78, for a total transaction of $3,754,051.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,388 shares of company stock valued at $18,198,482. Insiders own 3.30% of the company’s stock.

AVGO has been the subject of several recent research reports. KeyCorp raised their target price on shares of Broadcom from $310.00 to $330.00 and gave the company an “overweight” rating in a report on Friday, August 9th. DA Davidson lowered their price target on shares of Broadcom to $300.00 and set a “buy” rating for the company in a report on Friday, June 14th. Robert W. Baird lowered their price target on shares of Broadcom from $300.00 to $280.00 and set an “outperform” rating for the company in a report on Monday, June 17th. SunTrust Banks lowered their price target on shares of Broadcom to $307.00 and set a “buy” rating for the company in a report on Friday, June 14th. Finally, Daiwa Capital Markets downgraded shares of Broadcom from a “buy” rating to a “neutral” rating in a report on Thursday, August 15th. Ten investment analysts have rated the stock with a hold rating and twenty-nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $304.32.

NASDAQ AVGO opened at $275.57 on Wednesday. The company’s fifty day simple moving average is $283.20 and its 200-day simple moving average is $286.23. Broadcom Inc has a 52 week low of $208.23 and a 52 week high of $323.20. The company has a current ratio of 1.26, a quick ratio of 1.13 and a debt-to-equity ratio of 1.53. The stock has a market cap of $108.33 billion, a P/E ratio of 14.63, a PEG ratio of 1.33 and a beta of 0.92.

Broadcom (NASDAQ:AVGO) last posted its earnings results on Thursday, June 13th. The semiconductor manufacturer reported $5.21 EPS for the quarter, topping analysts’ consensus estimates of $5.18 by $0.03. Broadcom had a net margin of 15.92% and a return on equity of 32.81%. The business had revenue of $5.52 billion for the quarter, compared to analysts’ expectations of $5.70 billion. During the same period in the previous year, the company posted $4.88 earnings per share. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, research analysts expect that Broadcom Inc will post 17.23 EPS for the current fiscal year.

Broadcom Company Profile

Broadcom Inc designs, develops, and supplies a range of semiconductor devices with a focus on complex digital and mixed signal complementary metal oxide semiconductor based devices and analog III-V based products worldwide. The company operates through four segments: Wired Infrastructure, Wireless Communications, Enterprise Storage, and Industrial & Other.

Further Reading: How is the LIBOR rate calculated?

Want to see what other hedge funds are holding AVGO?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc (NASDAQ:AVGO).

Institutional Ownership by Quarter for Broadcom (NASDAQ:AVGO)

Receive News & Ratings for Broadcom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Broadcom and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity …

Amendments to the Corporation Stock Option Plan and Equity Incentive … to the Corporation’s stock option plan (the “Stock Option Plan”) in order to …

LAVAL, Quebec, Aug. 28, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), announces the voting results for the matters listed in its management circular dated July 24, 2019 held at its Annual and Special Meeting of Shareholders, in Laval, Canada on August 27, 2019 (the “AGM”).

For further information on the voting results of the resolution passed during the AGM, please refer to the Report of Voting Results available on SEDAR.

Election of Directors

At the AGM, the following individuals were elected as directors of the Corporation for the ensuing year: Roderick N. Carter, Jean-Marie (John) Canan, Jan D’Alvise and Donald Olds.

Appointment of Auditors

At the AGM, KPMG LLP were appointed as the Corporation’s auditors for the ensuing fiscal year and the directors were authorized to fix their remuneration.

Amendments to the Corporation Stock Option Plan and Equity Incentive Plan

At the AGM, disinterested shareholders approved amendments to the Corporation’s stock option plan (the “Stock Option Plan”) in order to increase the fixed number of common shares (the “Common Shares”) that may be issued upon the exercise of all options granted under the plan, from 5,494,209 (representing 15% of the number of Common Shares issued and outstanding, as of June 27, 2018) to 11,719,910 Common Shares (representing 15% of the issued and outstanding Common Shares as of April 9, 2019), which number includes 5,041,628 Common Shares reserved for outstanding options under the Stock Option Plan as at July 23, 2019.

At the AGM, disinterested shareholders also approved amendments to the Corporation’s equity incentive plan (the “Equity Incentive Plan”) in order to set the total number of Common Shares reserved for issuance pursuant to awards granted under the Equity Incentive Plan to an aggregate number that if, and for so long as the Common Shares are listed on the TSX-V, shall not exceed the lower of (x) 1,953,318 Common Shares (representing 2.5% of the number of Common Shares issued and outstanding as of April 9, 2019), up from 915,701 Common Shares (representing 2.5% of the number of Common Shares issued and outstanding as of June 27, 2018), and (y) 15% of the issued and outstanding Common Shares as of April 9, 2019, representing 11,719,910 Common Shares (up from 5,494,209 Common Shares representing 15% of the number of Common Shares issued and outstanding as of June 27, 2018), which number shall include Common Shares issuable pursuant to options issued under the Stock Option Plan.

The amendments to the Stock Option Plan and the Equity Incentive Plan are subject to TSX-V final approval.

Ratification of Stock Option Grants

At the AGM, disinterested shareholders passed a resolution to approve, ratify and confirm a previous grant of a total of 1,362,900 options to purchase Common Shares of the Corporation to certain directors and officers of the Corporation, as further described in the management proxy circular dated July 24, 2019.

About CaPre (omega-3 phospholipid)

Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body. Acasti believes that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the EPA and DHA contained in fish oil that are transported either by triglycerides (as in dietary supplements) or as ethyl esters in other prescription omega-3 drugs, which must then undergo additional digestion before they are ready for transport in the bloodstream. Clinically, the phospholipids may not only improve the absorption, distribution, and metabolism of omega-3s, but they may also decrease the synthesis of LDL cholesterol in the liver, impede or block cholesterol absorption, and stimulate lipid secretion from bile. In two Phase 2 studies, CaPre achieved a statistically significant reduction of triglycerides and non-HDL cholesterol levels in patients across the dyslipidemia spectrum from patients with mild to moderate hypertriglyceridemia (patients with TG blood levels between 200mg/dl and 500mg/dl) to patients with severe hypertriglyceridemia (those with TG levels above 500mg/dl). Furthermore, in the Phase 2 studies, CaPre demonstrated the potential to actually reduce LDL, or “bad cholesterol”, as well as the potential to increase HDL, or “good cholesterol”, especially at the therapeutic dose of 4 grams/day. The Phase 2 data also showed a significant reduction of HbA1c at a 4 gram dose, suggesting that due to its unique omega-3/phospholipid composition, CaPre may actually improve long-term glucose metabolism. Acasti’s TRILOGY Phase 3 program is currently underway.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. The addressable market may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going third party outcomes studies. Acasti may need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre’s indications to this segment. Acasti’s strategy is to commercialize CaPre in the U.S. and the company is pursuing development and distribution partnerships to market CaPre in major countries around the world. For more information, visit www.acastipharma.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking statements in this press release include, but are not limited to, information or statements about Acasti’s strategy, future operations, prospects and the plans of management; Acasti’s ability to conduct all required clinical and non-clinical trials for CaPre, including the timing and results of those trials; CaPre’s potential to become the “best-in-class” cardiovascular drug for treating severe Hypertriglyceridemia (HTG), Acasti’s ability to commercially launch CaPre, and Acasti’s ability to fund its continued operations.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the “Cautionary Note Regarding Forward-Looking Information” section contained in Acasti’s latest annual report on Form 20-F and most recent management’s discussion and analysis (MD&A), which are available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar/shtml, and on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions, including Acasti’s latest annual report on Form 20-F and most recent MD&A.

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact:

Jan D’Alvise

Chief Executive Officer

Tel: 450-686-4555

Email: info@acastipharma.com

www.acastipharma.com

U.S. Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ACST@crescendo-ir.com

Related Posts:

  • No Related Posts